Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) — VMCI valuation read

Composite valuation read on 002550.SZ: VMCI 56/100 against a Healthcare sector median of 50. The 6-point above-median print is the headline number for Changzhou Qianhong Biopharma CO.,LTD, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 002550.SZ: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 002550.SZ: 002550.SZ trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 3.1x is the binding constraint on the bear case. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

002550.SZ rose 3.3% over the trailing 7 days, with a -0.5% read on a 30-day basis.